Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia
Department of Pharmacology, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia
Divison of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia
Author to whom correspondence should be addressed.
Academic Editor: David Wong
Received: 14 January 2021 / Revised: 18 March 2021 / Accepted: 26 March 2021 / Published: 1 April 2021
Triple-negative breast cancer (TNBC) represents a heterogeneous group of breast cancers that lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal factor 2 (HER2) amplifications. This triple negativity represents a challenge in choosing the right treatment, as without the aforementioned biomarkers there are no efficient therapeutic targets. Nevertheless, some triple-negative breast cancers express androgen receptor (AR), which could be used as a novel therapeutic target in such subgroup of breast cancers. In our review, we aimed to identify clinical features and proposed potential therapeutic approaches of this specific subgroup—AR-positive triple-negative breast cancer. Our findings contributed to a better understanding of the current problematics regarding AR-positive TNBC.